Liraglutide

01 · What it is

Liraglutide is the oldest compound in this family, the smallest in effect, and the only one whose literature contains a randomised comparison against not eating as much.

That trial, published in 2023, randomised adults with obesity and prediabetes to liraglutide, to caloric restriction, or to sitagliptin. Weight loss of at least 5% of baseline occurred in 44% of the caloric restriction group, 22% of the liraglutide group and 5% of the sitagliptin group (p = 0.02). The ratio of fat to lean mass fell by 6.5% under caloric restriction and 2.2% on liraglutide ¹⁰.

The supervised diet outperformed the drug on both measures. That result is one trial, in one population, with a comparator that is not what most people mean by dieting — a monitored caloric restriction protocol is an intervention, not an intention. It is reported here because it is in the peer-reviewed record, because it is almost never quoted, and because a family of guides that reports only the numbers pointing one way is not reporting the literature.

What it is. Liraglutide is a once-daily GLP-1 receptor agonist and the first of its class to be widely used for weight management. Its trial programme, SCALE, ran from 2013 through at least 2025 and covers weight maintenance ¹, obstructive sleep apnoea ², three-year diabetes prevention in prediabetes ³, primary-care behavioural therapy ⁴, type 2 diabetes on basal insulin ⁵, and children aged 6 to under 12 ¹⁵.

It has since been displaced in every head-to-head located here. Semaglutide produced greater weight loss in STEP 8 ⁸. Tirzepatide produced better results across weight and cardiometabolic measures in a 2026 Bayesian network meta-analysis, with a broadly similar safety profile across all three ²⁰. A cost-effectiveness analysis frames tirzepatide against liraglutide rather than the reverse ¹⁸.

The displacement is the honest frame for this compound. Liraglutide is not a failed drug; it is an approved one that worked, was studied thoroughly, and has been superseded. That trajectory is what regulated development looks like from the inside, and it is not available to any unapproved compound, which never gets superseded because it never gets established.

02 · Evidence at a glance

Evidence grade

Approved Pharma — extensive randomised evidence across a named trial programme

What it is

A once-daily GLP-1 receptor agonist ¹⁶

Versus caloric restriction

≥5% weight loss in 44% (caloric restriction) vs 22% (liraglutide) vs 5% (sitagliptin), p = 0.02; fat-to-lean ratio fell 6.5% vs 2.2% ¹⁰

Versus semaglutide

STEP 8, 68 weeks, head-to-head; endpoints included achieving ≥10%, ≥15% and ≥20% loss ⁸

Versus tirzepatide

Tirzepatide better across weight and cardiometabolic outcomes; safety profiles broadly similar ²⁰

SCALE Maintenance, 2013

Maintained diet-induced loss and induced further loss; cardiometabolic improvements “small but statistically significant” ¹

SCALE Sleep Apnea, 2016

Moderate or severe obstructive sleep apnoea in non-diabetic participants unwilling or unable to use CPAP ²

SCALE Obesity and Prediabetes, 2017

3 years; 2,254 randomised, 1,505 to liraglutide and 749 to placebo ³

SCALE Insulin, 2020

56 weeks, type 2 diabetes on basal insulin ⁵

SCALE IBT, 2020

First primary-care evaluation of the CMS behavioural-therapy benefit with or without the drug ⁴

SCALE Kids, 2025

Children 6 to <12. Adverse events 89% vs 88%; gastrointestinal 80% vs 54%; serious 12% vs 8% ¹⁵

Body composition

Visceral and ectopic fat at high cardiovascular risk ⁷; bone health after exercise, drug, or both ¹²

Cardiovascular outcome trial

Not retrieved in this search — see limitations

Off-indication research

Alcohol use disorder ¹⁴; bipolar disorder ¹¹; polycystic ovary syndrome ^6,19

Liver

Efficacy in steatohepatitis with limited histological improvement of fibrosis ¹³

Regulatory status

Prescription-only medicine

03 · Mechanism of action

A daily agonist, and the daily part matters

Liraglutide is a GLP-1 receptor agonist administered once daily, in contrast to the once-weekly agents that followed it ^17,20. GLP-1 receptor agonism reduces energy intake and improves glycaemic control; the pharmacological question that separates the members of this class is not which receptor but how long exposure is sustained and at what peak.

Dosing frequency is a real pharmacological variable here, not a convenience feature. A once-weekly agent produces a flatter exposure profile than a daily one, and the newer compounds’ larger effects come partly from what that profile permits.

Where the appetite effect has been measured directly

A 2025 phase 1 trial randomised 114 adults without diabetes and with a body mass index from 27 to 50 kg/m² to blinded once-weekly tirzepatide or placebo, or open-label once-daily liraglutide, with the primary outcome being change in energy intake from baseline to week 3 ¹⁷.

A short mechanistic trial measuring ingestive behaviour rather than weight is the right design for a mechanism question, and worth distinguishing from the outcome trials. It also has an open-label liraglutide arm against blinded comparators, which the authors report and a reader should weigh.

Body composition, not just body weight

Liraglutide 3.0 mg was studied for effects on visceral and ectopic fat in adults with overweight or obesity at high cardiovascular risk without type 2 diabetes, on the premise that visceral and ectopic fat are key drivers of adverse cardiometabolic outcomes ⁷. Separately, a randomised trial examined bone health after an 8-week 800 kcal/day diet, with participants then randomised for 52 weeks to exercise alone, liraglutide alone, the combination, or control ¹².

The bone study is the one to notice. Rapid weight loss affects bone, and a trial that asks the question rather than assuming the answer is doing something the promotional literature around this class does not. Its four-arm design also separates drug from exercise, which very few studies here do.

04 · Key research findings

Weight

SCALE Maintenance, 2013. After low-calorie-diet-induced loss, liraglutide with diet and exercise maintained the loss achieved by caloric restriction and induced further loss. Cardiometabolic improvements were small but statistically significant compared with placebo ¹.

The authors’ own adjective. “Small but statistically significant” is a phrase this project rarely gets to quote directly, and it is more informative than most effect sizes.

SCALE Obesity and Prediabetes, 2017. A three-year randomised, double-blind trial of liraglutide 3.0 mg for type 2 diabetes risk reduction and weight management in prediabetes, randomising 2,254 participants — 1,505 to drug and 749 to placebo — following an earlier 56-week trial in the same programme ³.

Three years is the longest follow-up in this entire family. Every newer compound’s evidence is shorter, and that is a genuine advantage of the older drug that its displacement in effect size does not erase.

SCALE IBT, 2020. The first primary-care evaluation of the Centers for Medicare and Medicaid Services intensive behavioural therapy benefit, delivered alone with placebo or in combination with liraglutide 3.0 mg ⁴.

SCALE Insulin, 2020. A 56-week randomised trial in people with overweight or obesity and type 2 diabetes treated with basal insulin ⁵.

Weight-loss maintenance with exercise, 2022. An exploratory analysis of eating- and physical activity-related outcomes from a randomised trial of maintenance with exercise, liraglutide, or the combination ⁹.

Versus caloric restriction, 2023. In adults with obesity and prediabetes, ≥5% weight loss occurred in 44% on caloric restriction, 22% on liraglutide and 5% on sitagliptin (p = 0.02); the fat-to-lean ratio fell 6.5%, 2.2% and less, respectively ¹⁰.

STEP 8, 2022. Weekly subcutaneous semaglutide versus daily liraglutide in adults with overweight or obesity without diabetes, with percentage change in body weight as the primary endpoint and achievement of ≥10%, ≥15% and ≥20% loss as confirmatory secondary endpoints at week 68 ⁸.

Bayesian network meta-analysis, 2026. Tirzepatide showed improved results across weight loss and cardiometabolic health factors compared with liraglutide, with a safety profile generally similar to both liraglutide and semaglutide ²⁰.

The synthesis for this system: liraglutide has the longest and most varied weight literature in this family and the smallest effect in it. Both facts are established by good trials, and neither cancels the other.

Paediatric

SCALE Kids, 2025. A randomised trial in children aged 6 to under 12 with obesity. Adverse events occurred in 89% of the liraglutide group and 88% of the placebo group; gastrointestinal adverse events were more common on liraglutide (80% versus 54%); serious adverse events were reported in 12% and 8% respectively ¹⁵.

Those figures deserve to be read as a set. Nearly everyone in both arms had an adverse event, which says as much about how adverse events are counted in paediatric trials as about the drug. The gastrointestinal gap — 80% against 54% — is the drug-attributable signal, and the serious-event difference is small in relative terms and reported without a confidence interval in what was read here.

Beyond weight and glycaemia

Polycystic ovary syndrome. A 2020 review positioned GLP-1 receptor agonists as a new avenue in obesity, polycystic ovary syndrome and infertility ⁶; a 2025 systematic review and meta-analysis evaluated whether liraglutide combined with metformin outperforms metformin alone on glycaemic control, lipids, body mass index and sex hormone profiles ¹⁹.

Bipolar disorder, 2024. A trial in individuals with obesity or overweight and stable bipolar disorder, with percent change in body weight as the primary outcome and eating psychopathology measures among the secondary outcomes ¹¹.

Alcohol use disorder, 2025. A study in JAMA Psychiatry examining repurposing, with alcohol use disorder hospitalisation as the primary outcome in a within-individual analysis ¹⁴.

Steatohepatitis, 2024. A review reporting efficacy for liraglutide and semaglutide in steatohepatitis management, albeit with limited histological improvement of fibrosis ¹³.

The synthesis: the off-indication literature is real research, not marketing, and its most useful feature is that it keeps reporting qualified results. Efficacy in steatohepatitis with limited fibrosis improvement is a partial finding stated as a partial finding.

Real-world and economic

Real-world review, 2025. Utilisation, clinical and comparative effectiveness, and adverse effects of the approved GLP-1-based weight-loss therapies — liraglutide, semaglutide and tirzepatide ¹⁶.

Cost-effectiveness, 2025. Tirzepatide versus liraglutide from a UK perspective, both adjunct to diet and exercise, with a subgroup analysis in liraglutide’s NICE-recommended population — a body mass index of at least 35 kg/m² with non-diabetic hyperglycaemia and high cardiovascular risk ¹⁸.

Worth noting for what it reveals about how the drug is positioned: liraglutide’s reimbursed population is defined narrowly, and the economic literature now treats it as the comparator rather than the subject.

05 · Evidence overview

06 · Safety profile

This section reports the existence and structure of the safety literature. It does not enumerate adverse effects, contraindications, warnings or monitoring requirements, which are matters for the product label and for prescribing clinicians. This guide has read abstracts rather than full trial safety reports.

Animal data. No preclinical toxicology paper was retrieved in this search.

Human data. The SCALE programme collected safety systematically across weight, sleep apnoea, diabetes, primary-care and paediatric populations ^1,2,3,4,5,15. The paediatric trial reports the most quotable figures: adverse events in 89% and 88% of the liraglutide and placebo groups, gastrointestinal events in 80% versus 54%, and serious events in 12% versus 8% ¹⁵. A 2026 network meta-analysis describes the safety profile of tirzepatide as generally similar to both liraglutide and semaglutide ²⁰. Real-world adverse-effect evidence exists for the class ¹⁶. Bone outcomes after weight loss with drug, exercise or both have been examined in a dedicated randomised analysis ¹².

The safety literature here is broader than for any other compound in this family, and the reason is time. Liraglutide has been in use longest, so more questions have been asked of it — including awkward ones about bone and about children.

What is genuinely unknown. Three things.

The cardiovascular outcome result, as located here. This guide’s search did not retrieve liraglutide’s cardiovascular outcome trial. That trial is widely understood to exist and this guide does not cite it, because citing a paper it has not retrieved would be exactly the failure this project refuses. Retrieving it is a verification item.

Long-term paediatric outcomes. One randomised trial in children aged 6 to under 12 was located ¹⁵. Nothing addresses what happens over years in that population.

Everything outside prescribed conditions. No published analysis located here examines the identity, purity, concentration or contamination status of any liraglutide-labelled material obtained outside a pharmacy supply chain.

07 · US regulatory status

Current as of 7 September 2026. Liraglutide is a prescription-only medicine, approved and marketed in the United States and other jurisdictions ¹⁶. It is not a controlled substance. In the United Kingdom, a 2025 economic analysis describes a NICE-recommended population defined by a body mass index of at least 35 kg/m² with non-diabetic hyperglycaemia and high cardiovascular risk ¹⁸.

This guide has not consulted FDA, EMA or NICE records directly, and makes no statement about specific approved indications, dosing, contraindications or warnings beyond what the cited publications state.

Supplying or obtaining prescription drugs outside a lawful prescription is unlawful in the United States and in most other jurisdictions.

Under the World Anti-Doping Code, competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. The cardiovascular outcome trial was not retrieved. The search term intended to find it matched the ordinary English word instead. This guide therefore reports no cardiovascular outcome result for liraglutide, and the omission reflects the search, not the literature.
2. The caloric-restriction comparison is a single trial ¹⁰. Its comparator was a supervised protocol rather than self-directed dieting, its population was adults with obesity and prediabetes, and the abstract read here does not give the sample size. The finding is reported because it is published and rarely quoted; it is not presented as settled.
3. One arm of the mechanistic trial was open-label while the comparators were blinded ¹⁷, which the authors state and which limits what the comparison can support.
4. The paediatric serious-adverse-event figures — 12% versus 8% — are reported without a confidence interval in what was read here ¹⁵, and the trial was not powered for that comparison.
5. “Small but statistically significant” is the SCALE Maintenance authors’ own description of the cardiometabolic effects ¹, and it should not be upgraded in the retelling.
6. The steatohepatitis claim is qualified in its source: efficacy with limited histological improvement of fibrosis ¹³. Biochemical or symptomatic improvement without histological fibrosis improvement is a partial result.
7. Sponsor involvement runs through the SCALE programme with recurring investigator groups ^1,2,3,4,5,15, as is normal for a registration programme. The cost-effectiveness analysis is framed from the perspective of the comparator’s manufacturer ¹⁸.
8. No preclinical toxicology was retrieved, so this guide reports no animal safety data.
9. The off-indication literature is heterogeneous — a review ⁶, a small psychiatric trial ¹¹, a database study ¹⁴, a meta-analysis of a combination ¹⁹ — and none of it establishes an approved use.
10. Fewer than twenty-five of roughly 2,144 records were examined.
11. This guide has read abstracts, not full texts, for every source cited.
12. Nothing is known about non-pharmacy material.

09 · Legal and regulatory appendix

This appendix applies to every compound in this family and is reproduced in each guide.

Prescription status. Liraglutide is a prescription-only medicine wherever it is approved. Obtaining, supplying, possessing for supply, importing or administering prescription medicines outside a lawful prescription is unlawful in the United States and in most other jurisdictions. This guide does not describe how to obtain the compound and takes no position on any supplier.

Compounded and unapproved preparations. Preparations labelled as liraglutide that are not approved products have no established relationship to the material used in the trials cited here. This guide located no published analysis of the identity, purity, concentration, sterility or contamination status of any such preparation. Nothing in the trial evidence described above should be read as applying to them.

Research-use labelling. Material labelled for laboratory research use is not manufactured, tested, or released to the standards applied to medicines intended for people, and such labelling does not make administration lawful or safe.

What this guide is. A description of the published peer-reviewed literature, written for readers who want to understand the state of the evidence. It is not medical advice, not a recommendation, not an endorsement, and not a substitute for a clinician who can assess an individual situation.

Editorial position. Arkham Labs publishes independently and earns through disclosed referral links. That commercial relationship is disclosed on every page carrying such a link and on the editorial standards page. It does not alter what the evidence says, and this guide leads with a trial in which a supervised diet beat the drug.

10 · References

1. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L; NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013 Nov;37(11):1443–1451.

   PMID 23812094 ↗

2. Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, Mignot E. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016 Aug;40(8):1310–1319.

   PMID 27005405 ↗

3. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017 Apr 8;389(10077):1399–1409.

   PMID 28237263 ↗

4. Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, Rubino D. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020 Mar;28(3):529–536.

   PMID 32090517 ↗

5. Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, Skovgaard D, Sugimoto D, Jensen C, Mosenzon O. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE Insulin randomized controlled trial. Diabetes Care. 2020 May;43(5):1085–1093.

   PMID 32139381 ↗

6. Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020 Aug 1;105(8):e2695–e2709. Review.

   PMID 32442310 ↗

7. Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, Rodder S, Pandey A, Joshi PH. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021 Sep;9(9):595–605.

   PMID 34358471 ↗

8. Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022 Jan 11;327(2):138–150.

   PMID 35015037 ↗

9. Jensen SBK, Janus C, Lundgren JR, Juhl CR, Sandsdal RM, Olsen LM, Andresen A, Borg SA, Jacobsen IC, Finlayson G, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. Nat Commun. 2022 Aug 15;13(1):4770.

   PMID 35970829 ↗

10. Silver HJ, Olson D, Mayfield D, Wright P, Nian H, Mashayekhi M, Koethe JR, Niswender KD, Luther JM, Brown NJ. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: a randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab. 2023 Aug;25(8):2340–2350.

    PMID 37188932 ↗

11. McElroy SL, Guerdjikova AI, Blom TJ, Mori N, Romo-Nava F. Liraglutide in obese or overweight individuals with stable bipolar disorder. J Clin Psychopharmacol. 2024 Mar–Apr;44(2):89–95.

    PMID 38227621 ↗

12. Jensen SBK, Sørensen V, Sandsdal RM, Lehmann EW, Lundgren JR, Juhl CR, Janus C, Ternhamar T, Stallknecht BM, Holst JJ, Jørgensen NR, Jensen JB, Madsbad S, Torekov SS. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024 Jun 3;7(6):e2416775.

    PMID 38916894 ↗

13. Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol. 2024 Dec 28;30(48):5205–5211. Review.

    PMID 39735270 ↗

14. Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025 Jan 1;82(1):94–98.

    PMID 39535805 ↗

15. Fox CK, Barrientos-Pérez M, Bomberg EM, Dcruz J, Gies I, Harder-Lauridsen NM, Jalaludin MY, Sahu K, Weimers P, Zueger T, Arslanian S; SCALE Kids Trial Group. Liraglutide for children 6 to <12 years of age with obesity — a randomized trial. N Engl J Med. 2025 Feb 6;392(6):555–565.

    PMID 39258838 ↗

16. Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2:66–88. Review.

    PMID 40196933 ↗

17. Martin CK, Carmichael OT, Carnell S, Considine RV, Kareken DA, Dydak U, Mattes RD, Scott D, Shcherbinin S, Nishiyama H, Knights A, Urva S, Biernat L, Pratt E, Haupt A, Mintun M, Otero Svaldi D, Milicevic Z, Coskun T. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025 Sep;31(9):3141–3150.

    PMID 40555748 ↗

18. Capehorn M, Johansson E, Davies A, Evans J, Godbeer F, van Hest N, Cotterill G, Tolley K. Cost-effectiveness of tirzepatide versus liraglutide, both adjunct to diet and exercise, for patients with obesity or overweight: a UK perspective. Adv Ther. 2025 Oct;42(10):5055–5071.

    PMID 40788459 ↗

19. Ling J, Wang T, Huang W, Zhen Y, Zhang M, Fang X, Song W, Du X. Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Diabetes Obes Metab. 2025 Nov;27(11):6139–6153.

    PMID 40855964 ↗

20. Ciudin A, Sapin H, Fan L, Dimitriadis GK, Zimner-Rapuch S, Curteis T, Clark LJ, Rubinstein M, Johansson E. Comparison of clinical efficacy and safety of tirzepatide, liraglutide and semaglutide in patients with obesity and without T2D: a Bayesian network meta-analysis of randomised controlled trials. Adv Ther. 2026 May;43(5):2090–2105.

    PMID 41820778 ↗